[18F]FDG-PET/CT radiomics for prediction of bone marrow involvement in mantle cell lymphoma: A retrospective study in 97 patients Journal Article


Authors: Mayerhoefer, M. E.; Riedl, C. C.; Kumar, A.; Dogan, A.; Gibbs, P.; Weber, M.; Staber, P. B.; Huicochea Castellanos, S.; Schöder, H.
Article Title: [18F]FDG-PET/CT radiomics for prediction of bone marrow involvement in mantle cell lymphoma: A retrospective study in 97 patients
Abstract: Biopsy is the standard for assessment of bone marrow involvement in mantle cell lymphoma (MCL). We investigated whether [18F]FDG-PET radiomic texture features can improve prediction of bone marrow involvement in MCL, compared to standardized uptake values (SUV), and whether combination with laboratory data improves results. Ninety-seven MCL patients were retrospectively included. SUVmax, SUVmean, SUVpeak and 16 co-occurrence matrix texture features were extracted from pelvic bones on [18F]FDG-PET/CT. A multi-layer perceptron neural network was used to compare three combinations for prediction of bone marrow involvement—the SUVs, a radiomic signature based on SUVs and texture features, and the radiomic signature combined with laboratory parameters. This step was repeated using two cut-off values for relative bone marrow involvement: REL > 5% (>5% of red/cellular bone marrow); and REL > 10%. Biopsy demonstrated bone marrow involvement in 67/97 patients (69.1%). SUVs, the radiomic signature, and the radiomic signature with laboratory data showed AUCs of up to 0.66, 0.73, and 0.81 for involved vs. uninvolved bone marrow; 0.68, 0.84, and 0.84 for REL ≤ 5% vs. REL > 5%; and 0.69, 0.85, and 0.87 for REL ≤ 10% vs. REL > 10%. In conclusion, [18F]FDG-PET texture features improve SUV-based prediction of bone marrow involvement in MCL. The results may be further improved by combination with laboratory parameters. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords: bone marrow; lymphoma; fdg; pet/ct
Journal Title: Cancers
Volume: 12
Issue: 5
ISSN: 2072-6694
Publisher: MDPI  
Date Published: 2020-05-01
Start Page: 1138
Language: English
DOI: 10.3390/cancers12051138
PROVIDER: scopus
PUBMED: 32370121
PMCID: PMC7281173
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Christopher Riedl
    60 Riedl
  2. Heiko Schoder
    550 Schoder
  3. Anita Kumar
    195 Kumar
  4. Ahmet Dogan
    467 Dogan
  5. Peter Gibbs
    33 Gibbs